LASN01 represents a highly specialized first-in-class humanized monoclonal antibody specifically engineered to target the human interleukin-11 receptor alpha subunit with exceptional binding affinity and selectivity, effectively facilitating the measurable blockade of IL-11-mediated signaling pathways across various preclinical experimental models to evaluate the inhibition of fibroinflammatory processes in specialized research environments.